TSH Biopharm (ROCO:8432) Total Liabilities: NT$234 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:8432 TSH Biopharm Corp Ltd ROCO:8432
86 GF Score
Price NT$50.20
GF Value NT$78.94
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is TSH Biopharm Total Liabilities?

TSH Biopharm ROCO:8432 86 Total Liabilities is NT$234 Mil as of Dec. 2025. GuruFocus rates ROCO:8432 with a GF Score™ of 86/100 and a GF Value™ of NT$78.94 (Significantly Undervalued). The stock has 1 warning sign investors should review.

TSH Biopharm's Total Liabilities for the quarter that ended in Dec. 2025 was NT$234 Mil.

TSH Biopharm's quarterly Total Liabilities increased from Jun. 2025 (NT$273.54 Mil) to Sep. 2025 (NT$317.81 Mil) but then declined from Sep. 2025 (NT$317.81 Mil) to Dec. 2025 (NT$233.79 Mil).

TSH Biopharm's annual Total Liabilities increased from Dec. 2023 (NT$133.63 Mil) to Dec. 2024 (NT$219.23 Mil) and increased from Dec. 2024 (NT$219.23 Mil) to Dec. 2025 (NT$233.79 Mil).

TSH Biopharm Total Liabilities Historical Data

* Premium members only.

The historical data trend for TSH Biopharm's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TSH Biopharm Total Liabilities Chart

TSH Biopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 85.80 222.46 133.63 219.23 233.79

TSH Biopharm Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 219.23 236.80 273.54 317.81 233.79
ROCO:8432
86GF Score
TSH Biopharm Corp Ltd ROCO:8432
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TSH Biopharm Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

TSH Biopharm's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=227.091+(6.695+-7.105427357601E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=234

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1951.454-1717.668
=234

TSH Biopharm's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=227.091+(6.695+-7.105427357601E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=234

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=1951.454-1717.668
=234

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of NT$234 Mil mean?
TSH Biopharm (ROCO:8432) has a Total Liabilities of NT$234 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for TSH Biopharm and its competitors.
Is TSH Biopharm's Total Liabilities too high?
TSH Biopharm's current Total Liabilities is NT$234 Mil. Overall, TSH Biopharm has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's Total Liabilities compare to ZTS and UTHR?
TSH Biopharm's Total Liabilities of NT$234 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for TSH Biopharm and its competitors. TSH Biopharm's current Total Liabilities is NT$234 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$78.94, compared to a current price of NT$50.20 — trading 36.4% below its estimated fair value. The current Total Liabilities is NT$234 Mil. TSH Biopharm's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current Total Liabilities is NT$234 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TSH Biopharm (ROCO:8432) Overvalued in 2026?

Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued. The current stock price of NT$50.20 is trading 36.4% below its estimated GF Value™ of NT$78.94. GuruFocus considers TSH Biopharm to be Significantly Undervalued.

Key valuation signals for ROCO:8432:

  • Total Liabilities: NT$234 Mil
  • GF Value™: NT$78.94 vs. price of NT$50.20 (36.4% below fair value)
  • GF Score™: 86/100 with 1 warning sign

No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TSH Biopharm Business Description

Address No.3-1, Park Street, 3rd Floor-1, Nangang District, Taipei, TWN, 115
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
86GF Score

Get the complete analysis for ROCO:8432

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$50.20
Price
NT$78.94
GF Value